Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review
Description
Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company engaged in the development, production, and marketing of generic and innovative medicines. Its main activities include manufacturing generic drugs, biosimilars, and innovative medicines, related to therapy areas of central nervous system disorders, neurodegenerative conditions, and movement disorders, dermatology, women’s health, respiratory diseases, other disease conditions, and oncology including leukemia and types of non-Hodgkin’s lymphoma. It offers medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. It also provides over-the-counter (OTC) products and focuses on developing generic drugs. The company operates through a network of subsidiaries in North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
Teva Pharmaceutical Industries Ltd Key Recent Developments
Apr 30,2026: Teva's 2025 Healthy Future Report Highlights Environmental Progress and Access to Medicines
Apr 29,2026: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
Apr 29,2026: Teva Reports Strong Q1 2026 Results Driven by Innovative Portfolio Growth
Apr 29,2026: Medincell Partner Teva Reports UZEDY Net Sales of $63M in Q1 2026, Up 62%
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Opportunities thaented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company engaged in the development, production, and marketing of generic and innovative medicines. Its main activities include manufacturing generic drugs, biosimilars, and innovative medicines, related to therapy areas of central nervous system disorders, neurodegenerative conditions, and movement disorders, dermatology, women’s health, respiratory diseases, other disease conditions, and oncology including leukemia and types of non-Hodgkin’s lymphoma. It offers medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. It also provides over-the-counter (OTC) products and focuses on developing generic drugs. The company operates through a network of subsidiaries in North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
Teva Pharmaceutical Industries Ltd Key Recent Developments
Apr 30,2026: Teva's 2025 Healthy Future Report Highlights Environmental Progress and Access to Medicines
Apr 29,2026: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
Apr 29,2026: Teva Reports Strong Q1 2026 Results Driven by Innovative Portfolio Growth
Apr 29,2026: Medincell Partner Teva Reports UZEDY Net Sales of $63M in Q1 2026, Up 62%
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Opportunities thaented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
90 Pages
- Section 1 - About the Company
- Teva Pharmaceutical Industries Ltd - Key Facts
- Teva Pharmaceutical Industries Ltd - Key Employees
- Teva Pharmaceutical Industries Ltd - Key Employee Biographies
- Teva Pharmaceutical Industries Ltd - Major Products and Services
- Teva Pharmaceutical Industries Ltd - History
- Teva Pharmaceutical Industries Ltd - Company Statement
- Teva Pharmaceutical Industries Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Business Unit
- Section 2 – Company Analysis
- Company Overview
- Teva Pharmaceutical Industries Ltd - Business Description
- Geographical Segment: Europe
- Target Markets
- Performance
- Overview
- Geographical Segment: International Markets
- Target Markets
- Performance
- Overview
- Geographical Segment: Other Activities
- Performance
- Overview
- Geographical Segment: United States
- Target Markets
- Performance
- Overview
- R&D Overview
- Teva Pharmaceutical Industries Ltd - Corporate Strategy
- Teva Pharmaceutical Industries Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Teva Pharmaceutical Industries Ltd - Strengths
- Teva Pharmaceutical Industries Ltd - Weaknesses
- Teva Pharmaceutical Industries Ltd - Opportunities
- Teva Pharmaceutical Industries Ltd - Threats
- Teva Pharmaceutical Industries Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Teva Pharmaceutical Industries Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Apr 30, 2026: Teva's 2025 Healthy Future Report Highlights Environmental Progress and Access to Medicines
- Apr 29, 2026: Medincell Partner Teva Reports UZEDY Net Sales of $63M in Q1 2026, Up 62%
- Apr 29, 2026: Teva Reports Strong Q1 2026 Results Driven by Innovative Portfolio Growth
- Apr 29, 2026: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
- Apr 15, 2026: Teva Launches Home Ground Schizophrenia Community Online Resource for People With Schizophrenia and Care Partners
- Apr 14, 2026: Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
- Mar 31, 2026: Teva receives FDA approval for Prolia biosimilar
- Mar 30, 2026: Teva Gains Biosimilar Momentum With FDA Approval of PONLIMSI and Filing Acceptance for Xolair Biosimilar
- Mar 30, 2026: Teva Advances Biosimilars With FDA Approval of PONLIMSI and Filing Acceptances for Xolair Biosimilar
- Mar 19, 2026: Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Teva Pharmaceutical Industries Ltd, Key Facts
- Teva Pharmaceutical Industries Ltd, Key Employees
- Teva Pharmaceutical Industries Ltd, Key Employee Biographies
- Teva Pharmaceutical Industries Ltd, Major Products and Services
- Teva Pharmaceutical Industries Ltd, History
- Teva Pharmaceutical Industries Ltd, Subsidiaries
- Teva Pharmaceutical Industries Ltd, Joint Venture
- Teva Pharmaceutical Industries Ltd, Business Unit
- Teva Pharmaceutical Industries Ltd, Key Competitors
- Teva Pharmaceutical Industries Ltd, Ratios based on current share price
- Teva Pharmaceutical Industries Ltd, Annual Ratios
- Teva Pharmaceutical Industries Ltd, Annual Ratios (Cont...1)
- Teva Pharmaceutical Industries Ltd, Annual Ratios (Cont...2)
- Teva Pharmaceutical Industries Ltd, Interim Ratios
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Teva Pharmaceutical Industries Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Teva Pharmaceutical Industries Ltd, Performance Chart (2021 - 2025)
- Teva Pharmaceutical Industries Ltd, Ratio Charts
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
